2.17p-0.11 (-4.89%)04 Jul 2025, 16:30
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Immupharma PLC Fundamentals

Company NameImmupharma PLCLast Updated2025-07-04
IndustryBiotechnologySectorHealthcare
Shares in Issue416.437 mMarket Cap£8.91 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.01EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio-1.7998Cash Equity Ratio-0.4364
Quick Ratio0.2807Current Ratio0.58
Price To Book Value0ROCE0

Immupharma PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Immupharma PLC Company Financials

Assets202420232022
Tangible Assets£82,321.00£102,075.00£389,718.00
Intangible Assets£9,822.00£447,571.00£473,892.00
Investments0£643,781.00£688,350.00
Total Fixed Assets£92,143.00£1.38 m£1.64 m
Stocks000
Debtors£189,665.00£451,546.00£649,401.00
Cash & Equivalents£236,902.00£208,481.00£667,813.00
Other Assets0£184,785.00£83,790.00
Total Assets£977,011.00£2.72 m£3.97 m
Liabilities202420232022
Creditors within 1 year£1.52 m£1.67 m£1.45 m
Creditors after 1 year000
Other Liabilities000
Total Liabilities£1.52 m£1.67 m£1.45 m
Net assets-£542,859.00£1.06 m£2.52 m
Equity202420232022
Called up share capital£29.81 m£29.81 m£28.98 m
Share Premium£29.32 m£29.32 m£28.79 m
Profit / Loss-£2.78 m-£3.42 m-£4.46 m
Other Equity-£542,859.00£1.06 m£2.52 m
Preference & Minorities000
Total Capital Employed-£542,859.00£1.06 m£2.52 m
Ratios202420232022
Debt Ratio000
Debt-to-Equity000
Assets / Equity-1.7998-1.7998-1.7998
Cash / Equity-0.4364-0.4364-0.4364
EPS-£0.01-£0.01-£0.01
Cash Flow202420232022
Cash from operating activities-£1.77 m-£1.36 m-£2.35 m
Cashflow before financing-£1.27 m-£642,311.00-£799,335.00
Increase in Cash£24,547.00-£453,549.00-£876,759.00
Income202420232022
Turnover000
Cost of sales000
Gross Profit000
Operating Profit-£2.68 m-£3.06 m-£3.03 m
Pre-Tax profit-£2.78 m-£3.42 m-£4.46 m

Immupharma PLC Company Background

SectorHealthcare
ActivitiesImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease, and other candidates are P140 CIDP and BioAMB Fungal infections.
Latest Interim Date9 Sep 2024
Latest Fiscal Year End Date19 May 2025

Immupharma PLC Directors

AppointedNamePosition
2021-07-30Dr. Franco Di MuzioNon-Executive Director
2006-03-31Mr. Douglas Gordon James PatersonNon-Executive Director
2025-05-19Mr. Timothy Paul McCarthyExecutive Director,Chairman and Chief Executive Officer
2021-07-30Mr. Dimitri DimitriouExecutive Director,Chief Executive Officer
2021-05-24Dr. Robert Henri ZimmerExecutive Director,President and Chief Scientific Officer
2016-05-05Mr. Richard Leonard WarrExecutive Director,Chairman
2016-05-05Dr. Ajay AgrawalNon-Executive Director
2011-08-09Mr. Paddy Hugh Walker-Taylor FCA,MCTExecutive Director,Chief Financial Officer
2006-03-31Mr. Anthony Johnson B.Pharm,MScNon-Executive Director
2023-08-11Dr. Sanjeev PandyaNon-Executive Director,Senior Independent Director
2021-07-30Dr. Stephane Robert George MeryNon-Executive Director
2025-05-19Dr. Timothy Gary FranklinExecutive Director,Chief Operating Officer
2025-05-19Ms. Lisa BaderoonNon-Executive Director,Head of Investor Relations
2025-05-19Dr. Robert Reilly LaurenceNon-Executive Director,Senior Independent
2025-05-19Dr. Sebastien R. GoudreauNon-Executive Director

Immupharma PLC Contact Details

Company NameImmuPharma PLC
AddressOne Bartholomew Close, London, EC1A 7BL
Telephone+44 2071524080
Websitehttps://www.immupharma.co.uk

Immupharma PLC Advisors

StockbrokerBryan, Garnier & Co Limited
Phone+44 2073322500
Nominated AdviserNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
StockbrokerNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
RegistrarComputershare Investor Services PLC
Phone+44 3707020003
Fax+44 3707036101
AuditorNexia Smith & Williamson
Phone+44 2071314000
Fax+44 2071314001
SolicitorBircham Dyson Bell
Phone+44 2072277000
Fax+44 2072223480
BankRoyal Bank of Scotland PLC
AuditorNexia Smith & Williamson Audit Limited